Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Emanuele Angelucci; Valeria Santini; Anna Angela Di Tucci; Giulia Quaresmini; Carlo Finelli; Antonio Volpe; Giovanni Quarta; Flavia Rivellini; Grazia Sanpaolo; Daniela Cilloni; Flavia Salvi; Giovanni Caocci; Alfredo Molteni; Daniele Vallisa; Maria Teresa Voso; Susanna Fenu; Lorenza Borin; Giancarlo Latte; Giuliana Alimena; Sergio Storti; Alfonso Piciocchi; Paola Fazi; Marco Vignetti; Sante Tura

doi:10.1111/ejh.12300

Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Emanuele Angelucci
, Valeria Santini
, Anna Angela Di Tucci
, Giulia Quaresmini
, Carlo Finelli
, Antonio Volpe
, Giovanni Quarta
, Flavia Rivellini
, Grazia Sanpaolo
, Daniela Cilloni
, Flavia Salvi
, Giovanni Caocci
, Alfredo Molteni
, Daniele Vallisa
, Maria Teresa Voso
, Susanna Fenu
, Lorenza Borin
, Giancarlo Latte
, Giuliana Alimena
, Sergio Storti

Alfonso Piciocchi, Paola Fazi, Marco Vignetti, Sante Tura

Università Cattolica del Sacro Cuore

AO Brotzu
University of Florence
Division of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII
Alma Mater Studiorum University of Bologna
Azienda Ospedaliera S.G. Moscati
Ospedale A. Perrino
U.O. Medicina Interna e Onco-Ematologica P.O. Umberto I
IRCCS Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG)
University of Turin
Division of Hematology, A.O. Nazionale Santi Antonio e Biagio e C. Arrigo
ATS Sardegna - ASSL Cagliari
Asst Grande Ospedale Metropolitano Niguarda
Division of Medical Oncology and Hematology, Hospital of Piacenza
Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino
Hematology University Division
ATS Sardegna - ASSL Nuoro
University of Rome La Sapienza
GIMEMA Foundation
University of Bologna

Risultato della ricerca: Contributo in rivista › Articolo › peer review

68 Citazioni (Scopus)

Abstract

In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Rivista	European Journal of Haematology
DOI	https://doi.org/10.1111/ejh.12300
Stato di pubblicazione	Pubblicato - 2014

Keywords

Chelation Therapy
Deferasirox (DFX)
Iron Chelation
Iron Overload
Myelodysplastic Syndromes
Safety
Serum Ferritin

Accesso al documento

10.1111/ejh.12300

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Angelucci, E., Santini, V., Di Tucci, A. A., Quaresmini, G., Finelli, C., Volpe, A., Quarta, G., Rivellini, F., Sanpaolo, G., Cilloni, D., Salvi, F., Caocci, G., Molteni, A., Vallisa, D., Voso, M. T., Fenu, S., Borin, L., Latte, G., Alimena, G., ... Tura, S. (2014). Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial). European Journal of Haematology, N/A-N/A. https://doi.org/10.1111/ejh.12300

@article{4721e5f14e5d415480aa6971f86c172d,

title = "Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)",

abstract = "In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.",

keywords = "Chelation Therapy, Deferasirox (DFX), Iron Chelation, Iron Overload, Myelodysplastic Syndromes, Safety, Serum Ferritin, Chelation Therapy, Deferasirox (DFX), Iron Chelation, Iron Overload, Myelodysplastic Syndromes, Safety, Serum Ferritin",

author = "Emanuele Angelucci and Valeria Santini and \{Di Tucci\}, \{Anna Angela\} and Giulia Quaresmini and Carlo Finelli and Antonio Volpe and Giovanni Quarta and Flavia Rivellini and Grazia Sanpaolo and Daniela Cilloni and Flavia Salvi and Giovanni Caocci and Alfredo Molteni and Daniele Vallisa and Voso, \{Maria Teresa\} and Susanna Fenu and Lorenza Borin and Giancarlo Latte and Giuliana Alimena and Sergio Storti and Alfonso Piciocchi and Paola Fazi and Marco Vignetti and Sante Tura",

year = "2014",

doi = "10.1111/ejh.12300",

language = "English",

pages = "N/A--N/A",

journal = "European Journal of Haematology",

issn = "1600-0609",

publisher = "John Wiley and Sons Inc.",

}

Angelucci, E, Santini, V, Di Tucci, AA, Quaresmini, G, Finelli, C, Volpe, A, Quarta, G, Rivellini, F, Sanpaolo, G, Cilloni, D, Salvi, F, Caocci, G, Molteni, A, Vallisa, D, Voso, MT, Fenu, S, Borin, L, Latte, G, Alimena, G, Storti, S, Piciocchi, A, Fazi, P, Vignetti, M & Tura, S 2014, 'Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)', European Journal of Haematology, pagg. N/A-N/A. https://doi.org/10.1111/ejh.12300

TY - JOUR

T1 - Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

AU - Angelucci, Emanuele

AU - Santini, Valeria

AU - Di Tucci, Anna Angela

AU - Quaresmini, Giulia

AU - Finelli, Carlo

AU - Volpe, Antonio

AU - Quarta, Giovanni

AU - Rivellini, Flavia

AU - Sanpaolo, Grazia

AU - Cilloni, Daniela

AU - Salvi, Flavia

AU - Caocci, Giovanni

AU - Molteni, Alfredo

AU - Vallisa, Daniele

AU - Voso, Maria Teresa

AU - Fenu, Susanna

AU - Borin, Lorenza

AU - Latte, Giancarlo

AU - Alimena, Giuliana

AU - Storti, Sergio

AU - Piciocchi, Alfonso

AU - Fazi, Paola

AU - Vignetti, Marco

AU - Tura, Sante

PY - 2014

Y1 - 2014

N2 - In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.

AB - In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.

KW - Chelation Therapy

KW - Deferasirox (DFX)

KW - Iron Chelation

KW - Iron Overload

KW - Myelodysplastic Syndromes

KW - Safety

KW - Serum Ferritin

KW - Chelation Therapy

KW - Deferasirox (DFX)

KW - Iron Chelation

KW - Iron Overload

KW - Myelodysplastic Syndromes

KW - Safety

KW - Serum Ferritin

UR - http://hdl.handle.net/10807/54453

U2 - 10.1111/ejh.12300

DO - 10.1111/ejh.12300

M3 - Article

SN - 1600-0609

SP - N/A-N/A

JO - European Journal of Haematology

JF - European Journal of Haematology

ER -

Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo